Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00982202 · ClinicalTrials.gov registry record · Phase 2
Pioglitazone in Alzheimer Disease
A Phase 2 study, sponsored by National Institute on Aging (NIA).
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00982202: Completed Phase 2 study, sponsored by National Institute on Aging (NIA).
NCT00982202 is a Phase 2 study that has completed, run by National Institute on Aging (NIA). The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00982202, a Phase 2 study, has completed, sponsored by National Institute on Aging (NIA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study was designed to assess the safety and tolerability of pioglitazone, an approved drug for type 2 diabetes, in non diabetic patients with Alzheimer's disease. It was also designed to generate preliminary information on whether pioglitazone might slow progression of Alzheimer's disease.
Interventions
- DRUG Placebo
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2002-01 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
What the finished NCT00982202 record still lists
NCT00982202 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00982202 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00982202 about?
NCT00982202 is a clinical study titled "Pioglitazone in Alzheimer Disease". This study was designed to assess the safety and tolerability of pioglitazone, an approved drug for type 2 diabetes, in non diabetic patients with Alzheimer's disease. It was also designed to generate preliminary information on whether pioglitazone might slow progression of Alzheimer's disease.
What is the current status of trial NCT00982202?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2002-01. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00982202?
The interventions under investigation include: Placebo (DRUG), pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00982202?
This trial is sponsored by National Institute on Aging (NIA), which has 131 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00982202's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia